Charalampous C, Shah D, Kumar S, Chakraborty R
Ann Hematol. 2024; 103(10):3881-3888.
PMID: 38630132
DOI: 10.1007/s00277-024-05733-9.
Tran E, Ledbetter L
J Thromb Thrombolysis. 2023; 55(4):721-728.
PMID: 36781620
DOI: 10.1007/s11239-023-02778-x.
Fotiou D, Dimopoulos M, Kastritis E
Cancers (Basel). 2022; 14(24).
PMID: 36551701
PMC: 9777181.
DOI: 10.3390/cancers14246216.
Covut F, Sanfilippo K
Hematology Am Soc Hematol Educ Program. 2022; 2022(1):363-367.
PMID: 36485142
PMC: 9820182.
DOI: 10.1182/hematology.2022000414.
De Stefano V, Larocca A, Carpenedo M, Cavo M, Di Raimondo F, Falanga A
Haematologica. 2022; 107(11):2536-2547.
PMID: 35861017
PMC: 9614522.
DOI: 10.3324/haematol.2022.280893.
The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies.
Comerford C, Glavey S, Quinn J, OSullivan J
J Thromb Haemost. 2022; 20(8):1766-1777.
PMID: 35644028
PMC: 9546473.
DOI: 10.1111/jth.15773.
Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma.
Comerford C, Glavey S, OSullivan J, Quinn J
Cancer Drug Resist. 2022; 5(1):214-228.
PMID: 35582539
PMC: 8992590.
DOI: 10.20517/cdr.2021.115.
Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients.
Barrett A, Quinn J, Lavin M, Thornton P, ODonnell J, Murphy P
J Clin Med. 2021; 10(16).
PMID: 34441832
PMC: 8396929.
DOI: 10.3390/jcm10163536.
Primary Thromboprophylaxis in Patients with Malignancies: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and....
Kirschner M, do O Hartmann N, Parmentier S, Hart C, Henze L, Bisping G
Cancers (Basel). 2021; 13(12).
PMID: 34200741
PMC: 8230401.
DOI: 10.3390/cancers13122905.
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Rutjes A, Porreca E, Candeloro M, Valeriani E, Di Nisio M
Cochrane Database Syst Rev. 2020; 12:CD008500.
PMID: 33337539
PMC: 8829903.
DOI: 10.1002/14651858.CD008500.pub5.
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Bradbury C, Craig Z, Cook G, Pawlyn C, Cairns D, Hockaday A
Blood. 2020; 136(9):1091-1104.
PMID: 32438407
PMC: 7453153.
DOI: 10.1182/blood.2020005125.
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma.
Merz M, Dechow T, Scheytt M, Schmidt C, Hackanson B, Knop S
Ann Hematol. 2020; 99(8):1709-1725.
PMID: 32296915
PMC: 7340649.
DOI: 10.1007/s00277-020-04023-4.
Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools.
Fotiou D, Gavriatopoulou M, Terpos E
Cancers (Basel). 2020; 12(1).
PMID: 31940972
PMC: 7016665.
DOI: 10.3390/cancers12010191.
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy.
Cornell R, Goldhaber S, Engelhardt B, Moslehi J, Jagasia M, Patton D
Front Oncol. 2019; 9:45.
PMID: 30873378
PMC: 6401636.
DOI: 10.3389/fonc.2019.00045.
